Solstice announced a $225M funding-supported advancement of a next-generation CTLA-4 asset into neoadjuvant treatment, following a capital-led syndicate backing the NewCo. The financing package and in-licensing structure reflect continued investor appetite for immuno-oncology assets moving toward combination-ready, earlier-line settings. In neoadjuvant cancer treatment, CTLA-4 strategies are often evaluated for their ability to shape the immune microenvironment before surgery and to potentially improve downstream outcomes. The move also signals that second-wave CTLA-4 biologics are competing on more specific differentiation points, including dosing, toxicity control, and biomarker-driven patient selection. For the market, the transaction emphasizes how early clinical assets can attract sizable capital when accompanied by clear development intent and a defined clinical phase plan. (Story coverage source: BioCentury Finance.)